Comparing Two Treatment Approaches for Locally Advanced Cervical Cancer: Chemotherapy Before Radiation Versus Standard Radiation

TANCER TAmilnadu Neoadjuvant CERvix trial Neoadjuvant Chemotherapy Followed By Chemoradiation And Image-guided Adaptive Brachytherapy Versus Standard Chemoradiation With Image-guided Adaptive Brachytherapy In Locally Advanced Cervical Cancer - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/111127

Enrollment

500

Registered

2026-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Neoadjuvant Chemotherapy Followed By Chemoradiation And Image-guided Adaptive Brachytherapy: Induction: Paclitaxel 80 mg/m2 + Carboplatin AUC 2 weekly for 6 weeks EBRT (BM-sparing I

Eligibility

Inclusion criteria

Inclusion criteria: Histologically confirmed squamous adeno or adenosquamous carcinoma FIGO stages IB3 to IVA Planned for curative chemoRT including MRI or TRUS based IGABT ECOG 0 1 and 2 Adequate organ function

Exclusion criteria

Exclusion criteria: Prior pelvic RT or chemotherapy Distant metastasis

Design outcomes

Primary

Measure	Time frame
Progression free SurvivalTimepoint: 2 year Progression free Survival	—

Secondary

Measure	Time frame
3-year overall survival (OS), defined as time from randomization to death from any cause 3-year local control (LC), defined as absence of local recurrence 3-year distant metastasis-free survival (DMFS) Acute hematologic toxicity, assessed weekly during treatment and up to 90 days post-treatment using CTCAE v5.0 Late toxicity, assessed beyond 90 days post-treatment Quality of life (QoL) assessed at baseline, end of treatment, 3 months, 6 months, 1 year, and 2 years using EORTC QLQ-C30 and CX24 Tumor regression analysis, defined as change in tumor size between simulation and brachytherapy, and its correlation with clinical outcomes Timepoint: 3 year OS, 3 year local control 3 year Distant metastases free survival Acute toxicity - within 90 days of starting treatment Chronic toxicity - after 90 days of treatment QOL - at baseline, end of treatment, 3months, 6 months, 1year, 2 years tumor regression analysis at the time of diagnosis and at the time of brachytherapy	—

Measure

Time frame

3-year overall survival (OS), defined as time from randomization to death from any cause 3-year local control (LC), defined as absence of local recurrence 3-year distant metastasis-free survival (DMFS) Acute hematologic toxicity, assessed weekly during treatment and up to 90 days post-treatment using CTCAE v5.0 Late toxicity, assessed beyond 90 days post-treatment Quality of life (QoL) assessed at baseline, end of treatment, 3 months, 6 months, 1 year, and 2 years using EORTC QLQ-C30 and CX24 Tumor regression analysis, defined as change in tumor size between simulation and brachytherapy, and its correlation with clinical outcomes Timepoint: 3 year OS, 3 year local control 3 year Distant metastases free survival Acute toxicity - within 90 days of starting treatment Chronic toxicity - after 90 days of treatment QOL - at baseline, end of treatment, 3months, 6 months, 1year, 2 years tumor regression analysis at the time of diagnosis and at the time of brachytherapy

—

Countries

India

Contacts

Public ContactRamya Rangarajan

TAMILNADU GOVERNMENT MULTI SUPER SPECIALITY HOSPITAL, OMANDURAR

ramyarronco@gmail.com09444167592

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026